REGENXBIO Inc. $RGNX Shares Sold by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC significantly reduced its holdings in REGENXBIO Inc. by 70.1%, ending with approximately 12,998 shares valued at $93,000.
• Insider trading activity included CEO Curran Simpson selling 7,624 shares for about $76,469, which represents a 3.12% decrease in his ownership.
• REGENXBIO reported a loss of ($1.38) EPS in the latest quarter, missing analysts' expectations, with total revenue of $21.36 million compared to estimates of $40.87 million.

Voya Investment Management LLC cut its position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 70.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,998 shares of the biotechnology company's stock after selling 30,504 shares during the period. Voya Investment Management LLC's holdings in REGENXBIO were worth $93,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new stake in REGENXBIO during the first quarter worth about $35,000. Brooklyn Investment Group grew its holdings in REGENXBIO by 163.7% in the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,466 shares during the period. Pallas Capital Advisors LLC acquired a new stake in REGENXBIO in the first quarter valued at approximately $74,000. Entropy Technologies LP acquired a new stake in REGENXBIO in the first quarter valued at approximately $107,000. Finally, GAMMA Investing LLC grew its holdings in REGENXBIO by 372.1% in the first quarter. GAMMA Investing LLC now owns 16,188 shares of the biotechnology company's stock valued at $116,000 after purchasing an additional 12,759 shares during the period. 88.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at REGENXBIO

In other news, CEO Curran Simpson sold 7,624 shares of REGENXBIO stock in a transaction on Monday, September 29th. The stock was sold at an average price of $10.03, for a total value of $76,468.72. Following the completion of the sale, the chief executive officer directly owned 236,973 shares of the company's stock, valued at approximately $2,376,839.19. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 12.79% of the company's stock.

REGENXBIO Stock Up 1.2%

RGNX stock opened at $9.77 on Thursday. The business has a fifty day moving average of $8.93 and a two-hundred day moving average of $8.52. The stock has a market cap of $493.48 million, a price-to-earnings ratio of -2.84 and a beta of 1.17. REGENXBIO Inc. has a 52-week low of $5.03 and a 52-week high of $12.22.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The business had revenue of $21.36 million for the quarter, compared to analyst estimates of $40.87 million. As a group, sell-side analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on RGNX shares. Barclays dropped their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a report on Friday, August 8th. Royal Bank Of Canada decreased their target price on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. HC Wainwright restated a "buy" rating and issued a $34.00 target price on shares of REGENXBIO in a research report on Monday, September 8th. Finally, Chardan Capital reiterated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Monday, September 8th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, REGENXBIO currently has an average rating of "Moderate Buy" and an average price target of $28.38.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.